Clinical Trials

Otsuka Pharmaceutical and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with…
Read More...

BioTime reported that an investigator-led clinical trial has successfully treated its first patient in a study of Premvia as a carrier for stromal vascular fraction cells (SVF) for the…
Read More...

Izun Pharmaceuticals Corporation announced that the results from a recently completed double blind, Phase 2 clinical study in oral mucositis indicated promising positive outcomes for…
Read More...

Titan Pharmaceuticals announced that the first patient has been treated in a Phase 1/2 trial of the company's ropinirole implant intended for the treatment of the signs and symptoms of…
Read More...

Kaleido Biosciences announced an agreement with CoreBiome, a genomics platform company focused on accelerating microbiome innovation with expert genomics and big-data analytics, to…
Read More...

The U.S. Food and Drug Administration announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the…
Read More...

Therapix Biosciences announced that it has entered into an exclusive agreement with Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and…
Read More...

NewLink Genetics announced that it has entered into a clinical collaboration agreement with AstraZeneca to evaluate the combination of indoximod, NewLink Genetics’ small molecule IDO…
Read More...

AstraZeneca has announced positive top-line results of the Phase III, PINNACLE 4 trial in which Bevespi Aerosphere (glycopyrronium and formoterol fumarate 14.4/9.6 µg) demonstrated a…
Read More...

Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, announced that it has treated the first…
Read More...

Provention Bio announced that it has entered into agreements with Janssen Pharmaceutica NV and Janssen Sciences Ireland UC to in-license two clinical-stage assets, PRV-6527…
Read More...

Regeneron Pharmaceuticals and Sanofi announced positive results from the Phase 3 CAFÉ study of DUPIXENT® (dupilumab) in adults with moderate-to-severe atopic dermatitis (AD) who are…
Read More...

Thrombolytic Science, LLC (TSI) announced the completion of a Phase 1 clinical trial of TS01, a new-generation clot-dissolving therapy aimed at the treatment of clot-induced diseases…
Read More...

MilliporeSigma announced that Celonic AG, a Swiss contract development and manufacturing organization (CDMO), is upgrading its manufacturing facility with five of MilliporeSigma's…
Read More...

Kura Oncology announced positive topline results from a Phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell…
Read More...

IRX Therapeutics presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society…
Read More...

Midatech Pharma has announced the submission of a clinical trial application (CTA) for a first in human study of its MTD201 programme in carcinoid cancer and acromegaly. The…
Read More...

Roche announced results from the global phase III ALUR study showing that Alecensa® significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by 85%…
Read More...

ViraCyte, LLC, a clinical stage biopharmaceutical company developing cellular immunotherapies for severe infections, announced publication of positive data from a Phase 2 clinical trial…
Read More...

Regeneron Pharmaceuticals announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), did not meet its primary endpoint of…
Read More...